



Network Life Sciences Inc. Announces Private Placement and Debt Settlement

Vancouver, B.C., June 1, 2016 – Network Life Sciences Inc. (CSE:NOI), (“**Network**”, “the **Company**”) announces that it has completed a private placement of \$400,000 by issuing units of securities at \$0.05/unit. Each unit is comprised of one common share and one share purchase warrant to purchase one additional common share at \$0.06 for a one year term from the date of issue. The Company will issue 8,000,000 shares and 8,000,000 warrants. The Company additionally has entered into shares-for-debt settlement agreements whereby it will issue up to 5,686,312 shares (“**Shares**”) to current creditors of the Company at \$0.05 per share for settlement of amounts due aggregating \$284,316. The shares-for-debt settlements and private placement shares and warrant shares will be subject to a 4-month and one day hold period.

About Network Life Sciences Inc.: Network has acquired and is currently selling a core portfolio of oncology generic products for the European markets with possible expansion to other territories. The Company is commercially focused and is dedicated to serving the oncology marketplace by understanding local market dynamics and its customers unmet needs.

Further Information

Further details are available under the Company’s profile on SEDAR at www.sedar.com, and the Company’s profile on the CSE’s website at www.cnsx.ca.

For further information please contact:

Bill Thomas, CFO, and Director

Telephone: (604) 649-5245

E-mail: info@networklifesciencesinc.com

Website: www.networklifesciencesinc.com

Canadian Securities Exchange (CSE): Symbol NOI

Deutsche Boerse Xetra - Frankfurt Stock Exchange: Symbol 2NY1; WKN#: A14VRA

Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company including future plans for the development and sale of oncological pharmaceutical products and the ebola test kit and the completion of the Consolidation. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and the Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the Canadian Securities Exchange, consumer sentiment towards the Company’s products, competition, and failure of counterparties to perform their contractual obligations. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize, including the Consolidation.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.